Insider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Purchases 3,600 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel bought 3,600 shares of the stock in a transaction dated Monday, April 7th. The stock was purchased at an average cost of $9.10 per share, for a total transaction of $32,760.00. Following the acquisition, the chief executive officer now owns 5,561,602 shares in the company, valued at $50,610,578.20. The trade was a 0.06 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Snehal Patel also recently made the following trade(s):

• On Friday, April 4th, Snehal Patel acquired 5,500 shares of Greenwich LifeSciences stock. The shares were bought at an average cost of $8.73 per share, for a total transaction of $48,015.00.
• On Friday, January 10th, Snehal Patel acquired 2,500 shares of Greenwich LifeSciences stock. The shares were bought at an average cost of $12.51 per share, for a total transaction of $31,275.00.

Greenwich LifeSciences Trading Up 4.0 %

Greenwich LifeSciences stock opened at $9.43 on Thursday. Greenwich LifeSciences, Inc. has a 1 year low of $8.06 and a 1 year high of $18.75. The company has a market cap of $123.96 million, a PE ratio of -11.79 and a beta of 1.76. The company’s 50-day moving average is $11.34 and its two-hundred day moving average is $12.62.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $38.00 target price on shares of Greenwich LifeSciences in a research report on Tuesday, February 11th.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in GLSI. State Street Corp raised its position in shares of Greenwich LifeSciences by 4.4% in the 3rd quarter. State Street Corp now owns 71,408 shares of the company’s stock valued at $1,026,000 after acquiring an additional 3,005 shares during the period. Barclays PLC raised its position in shares of Greenwich LifeSciences by 323.3% in the 3rd quarter. Barclays PLC now owns 8,560 shares of the company’s stock valued at $123,000 after acquiring an additional 6,538 shares during the period. Geode Capital Management LLC raised its position in shares of Greenwich LifeSciences by 4.6% in the 3rd quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock valued at $1,919,000 after acquiring an additional 5,861 shares during the period. Garden State Investment Advisory Services LLC acquired a new stake in shares of Greenwich LifeSciences in the 3rd quarter valued at approximately $253,000. Finally, JPMorgan Chase & Co. raised its position in shares of Greenwich LifeSciences by 172.0% in the 4th quarter. JPMorgan Chase & Co. now owns 7,061 shares of the company’s stock valued at $79,000 after acquiring an additional 4,465 shares during the period. 4.16% of the stock is currently owned by institutional investors and hedge funds.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.